The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England
Pneumococcal disease, presenting as invasive pneumococcal disease (IPD) or community-acquired pneumonia (CAP) is an important cause of illness and hospitalisation in the elderly. To reduce pneumococcal burden, since 2003, 65-year-olds in England have been offered a 23-valent pneumococcal polysacchar...
| Hlavní autoři: | , , , , , , , , , , , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
Elsevier
2024
|
| _version_ | 1826315164941549568 |
|---|---|
| author | Danelian, G Burton, L Bayley, T Sanchez-Marroquin, A Park, J Manley, H Choi, Y Andrews, N Ladhani, S Earnshaw, A Gritzfeld, JF Trotter, C Panovska-Griffiths, J |
| author_facet | Danelian, G Burton, L Bayley, T Sanchez-Marroquin, A Park, J Manley, H Choi, Y Andrews, N Ladhani, S Earnshaw, A Gritzfeld, JF Trotter, C Panovska-Griffiths, J |
| author_sort | Danelian, G |
| collection | OXFORD |
| description | Pneumococcal disease, presenting as invasive pneumococcal disease (IPD) or community-acquired pneumonia (CAP) is an important cause of illness and hospitalisation in the elderly. To reduce pneumococcal burden, since 2003, 65-year-olds in England have been offered a 23-valent pneumococcal polysaccharide vaccine (PPV23). This study compares the impact and cost-effectiveness (CE) of vaccination with the existing PPV23 vaccine to the new 15-and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20), targeting adults aged 65 or 75 years old. We developed a static Markov model for immunisation against pneumococcal disease, capturing different vaccine effectiveness and immunity waning assumptions, projecting the number of IPD/CAP cases averted over the thirty years following vaccination. Using an economic model and probabilistic sensitivity analysis we evaluated the CE of the different immunisation strategies at current vaccine list prices and the willingness-to-pay at a median threshold of £20,000/QALY and an uncertainty threshold of 90% of simulations below £30,000/QALY. PCV20 averted more IPD and CAP cases than PCV15 or PPV23 over the thirty years following vaccination: 353(360), 145(159) and 150(174) IPD and 581(673), 259(485) and 212(235) CAP cases at a vaccination age of 65(75) under base vaccine effectiveness assumptions. At the listed prices of PCV20 and PPV23 vaccines as of May 2023, both vaccines were cost-effective when vaccinating 65- or 75-year-olds with an ICER threshold of £20,000 per QALY. To achieve the same cost-effectiveness as PPV23, the additional cost of PCV20 should be less than £44(£91) at an ICER threshold of £20,000/QALY (£30,000/QALY) if vaccination age is 65 (or £54(£103) if vaccination age is increased to 75). We showed that both PPV23 and PCV20 were likely to be cost-effective. PCV20 was likely to avert more cases of pneumococcal disease in elderly adults in England than the current PPV23 vaccine, given input assumptions of a higher vaccine effectiveness and slower waning for PCV20. |
| first_indexed | 2024-12-09T03:20:42Z |
| format | Journal article |
| id | oxford-uuid:c1b47e82-6f3e-4b1b-b45c-477e1ffa992b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:20:42Z |
| publishDate | 2024 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:c1b47e82-6f3e-4b1b-b45c-477e1ffa992b2024-11-08T15:32:32ZThe impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in EnglandJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c1b47e82-6f3e-4b1b-b45c-477e1ffa992bEnglishSymplectic ElementsElsevier2024Danelian, GBurton, LBayley, TSanchez-Marroquin, APark, JManley, HChoi, YAndrews, NLadhani, SEarnshaw, AGritzfeld, JFTrotter, CPanovska-Griffiths, JPneumococcal disease, presenting as invasive pneumococcal disease (IPD) or community-acquired pneumonia (CAP) is an important cause of illness and hospitalisation in the elderly. To reduce pneumococcal burden, since 2003, 65-year-olds in England have been offered a 23-valent pneumococcal polysaccharide vaccine (PPV23). This study compares the impact and cost-effectiveness (CE) of vaccination with the existing PPV23 vaccine to the new 15-and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20), targeting adults aged 65 or 75 years old. We developed a static Markov model for immunisation against pneumococcal disease, capturing different vaccine effectiveness and immunity waning assumptions, projecting the number of IPD/CAP cases averted over the thirty years following vaccination. Using an economic model and probabilistic sensitivity analysis we evaluated the CE of the different immunisation strategies at current vaccine list prices and the willingness-to-pay at a median threshold of £20,000/QALY and an uncertainty threshold of 90% of simulations below £30,000/QALY. PCV20 averted more IPD and CAP cases than PCV15 or PPV23 over the thirty years following vaccination: 353(360), 145(159) and 150(174) IPD and 581(673), 259(485) and 212(235) CAP cases at a vaccination age of 65(75) under base vaccine effectiveness assumptions. At the listed prices of PCV20 and PPV23 vaccines as of May 2023, both vaccines were cost-effective when vaccinating 65- or 75-year-olds with an ICER threshold of £20,000 per QALY. To achieve the same cost-effectiveness as PPV23, the additional cost of PCV20 should be less than £44(£91) at an ICER threshold of £20,000/QALY (£30,000/QALY) if vaccination age is 65 (or £54(£103) if vaccination age is increased to 75). We showed that both PPV23 and PCV20 were likely to be cost-effective. PCV20 was likely to avert more cases of pneumococcal disease in elderly adults in England than the current PPV23 vaccine, given input assumptions of a higher vaccine effectiveness and slower waning for PCV20. |
| spellingShingle | Danelian, G Burton, L Bayley, T Sanchez-Marroquin, A Park, J Manley, H Choi, Y Andrews, N Ladhani, S Earnshaw, A Gritzfeld, JF Trotter, C Panovska-Griffiths, J The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England |
| title | The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England |
| title_full | The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England |
| title_fullStr | The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England |
| title_full_unstemmed | The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England |
| title_short | The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England |
| title_sort | impact and cost effectiveness of pneumococcal immunisation strategies for the elderly in england |
| work_keys_str_mv | AT daneliang theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT burtonl theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT bayleyt theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT sanchezmarroquina theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT parkj theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT manleyh theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT choiy theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT andrewsn theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT ladhanis theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT earnshawa theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT gritzfeldjf theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT trotterc theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT panovskagriffithsj theimpactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT daneliang impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT burtonl impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT bayleyt impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT sanchezmarroquina impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT parkj impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT manleyh impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT choiy impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT andrewsn impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT ladhanis impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT earnshawa impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT gritzfeldjf impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT trotterc impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland AT panovskagriffithsj impactandcosteffectivenessofpneumococcalimmunisationstrategiesfortheelderlyinengland |